AmnioAMP vs Rampart: What Wound Care Teams Should Know

The Short Answer: What Is the Difference Between AmnioAMP and Rampart?

Both AmnioAMP (NextGen Biologics) and Rampart DL Matrix (Rampart Medical) are dehydrated human amniotic membrane wound products stored at room temperature — neither is cryopreserved, and neither requires a freezer or cold-chain logistics. The meaningful difference between them is layer count and orientation:

• AmnioAMP is a single-layer dehydrated amniotic membrane. It is side-specific (the stromal/basement-membrane side contacts the wound bed) and is billed under HCPCS code Q4250 per square centimeter.
• Rampart DL Matrix is a dual-layer dehydrated amniotic membrane. It is non-side specific (either surface can contact the wound bed, simplifying placement) and is billed under HCPCS code Q4347 per square centimeter.

Both require a brief 2–3 minute rehydration in sterile saline before application. No published head-to-head clinical trial directly compares these two branded products. The decision between them should rest on wound geometry, handling preference, payer coding, and current product labeling — not on unsupported claims of clinical superiority. For readers new to the portfolio, start with what AmnioAMP is before the side-by-side.

Product Background: What Labels and Catalogs Tell Us

Because neither product publishes its full manufacturing dossier publicly, the most defensible starting points for a comparison are payer policy bulletins, distributor listings, and FDA correspondence — not marketing materials.

AmnioAMP

AmnioAMP-MP is described in payer clinical policy bulletins (including Aetna) as a decellularized dehydrated human amniotic membrane (DDHAM) derived from placental amnion, providing a collagen-rich extracellular matrix with cytokines and growth factors. It is a single-layer product billed under HCPCS Q4250 per square centimeter, with some coding guides citing a Medically Unlikely Edit (MUE) limit of 400 units per date of service. Available sizes range from 2×2 cm to 12×21 cm per distributor listings.

Regulatory note: The FDA issued a warning letter on June 5, 2023 to the entity marketing AmnioAMP-WJ, stating that the product did not meet the “homologous use” criteria under section 361 of the PHS Act. That letter addressed AmnioAMP-WJ specifically, not AmnioAMP-MP, but clinicians should confirm the current regulatory status of any specific product code before use.

Rampart DL Matrix

Rampart is listed by Rampart Medical and major distributors as a sterile, absorbable, dehydrated dual-layer human amniotic membrane wound matrix. It is stored at room temperature, is non-side specific in application, and carries HCPCS code Q4347. The product is indicated as a protective biologic barrier over full-thickness wounds including diabetic foot ulcers, venous leg ulcers, pressure injuries, surgical wounds, and burns.

Evidence note: The available clinical literature on Rampart is largely product-specific rather than peer-reviewed head-to-head. Claims about exact viable-cell percentages, growth-factor retention rates, or superiority over any other branded product should be treated as unsupported unless they can be traced to a published trial or the manufacturer’s current instructions for use (IFU).

Dehydrated vs. Cryopreserved: Why It Matters (and Why It Doesn't Differentiate These Two)

A common source of confusion is the “dehydrated vs. cryopreserved” framing. This distinction is real and important for the broader amniotic membrane market — cryopreserved products (e.g., some Grafix configurations) are stored frozen and require a validated cold chain, while dehydrated products are room-temperature stable. But it does not differentiate AmnioAMP from Rampart, because both are dehydrated.

The most relevant processing comparison in the wound-care literature comes from a 2014 study in the Journal of Wound Care that directly compared cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue, finding that processing format alters matrix composition and the growth-factor profile (PMID: 25296347). This study does not compare AmnioAMP to Rampart, but it provides the mechanistic framework for why the same starting tissue can yield different clinical behavior depending on preservation method.

For dehydrated products specifically, the dehydration process removes moisture and eliminates viable cells but preserves the structural extracellular matrix (collagens I, III, IV, V; fibronectin; laminin; hyaluronic acid) and the growth factors bound to it (VEGF, PDGF, TGF-β, EGF, bFGF). Current research suggests that paracrine signaling from these matrix-bound molecules — not living cells — drives the wound-healing response of dehydrated membranes.

What the Clinical Evidence Actually Shows

Published amniotic-membrane evidence for diabetic foot ulcers (DFU), venous leg ulcers (VLU), and pressure injuries is encouraging but product-specific, often industry-sponsored, and rarely compares two branded products directly. Key studies that ground this comparison:

• A 2020 systematic review and meta-analysis of randomized controlled trials found that human amniotic membrane allograft improved DFU healing compared with standard care, including in patients with chronic non-healing wounds (PMID: 32119765).
• A 2024 retrospective-prospective trial of a non-viable (dehydrated) human amniotic membrane dressing reported clinical outcomes in chronic wound patients, emphasizing that the dehydrated, non-viable format can still support wound management (PMID: 39311338).
• A 2024 randomized controlled trial found that dehydrated amnion chorion membrane improved DFU healing rates versus standard of care (PMID: 38973638).
• A 2025 multi-centre randomized controlled trial assessed cryopreserved ultra-thick human amniotic membrane for complex DFUs, showing the cryopreserved format has been studied in this difficult population (PMID: 41346156).
• A 2022 systematic review and meta-analysis of amniotic membrane products for DFUs concluded the class shows promise but called for higher-quality, product-specific trials (PMID: 36104736).
• A 2025 network meta-analysis compared 12 interventions for diabetic foot ulcer treatment and ranked amniotic membrane therapies relative to other advanced modalities, providing the closest available comparative-effectiveness signal across the class (PMID: 40821981).

These studies support the class of amniotic membrane allografts as a therapeutic option for selected chronic wounds after standard care has stalled. They do not establish that AmnioAMP outperforms Rampart, or vice versa. Any side-by-side comparison that presents specific closure percentages, time-to-heal medians, or cost-per-square-centimeter differentials without a published source is unsupported and should not drive clinical or purchasing decisions.

For a deeper dive on AmnioAMP-specific outcomes data, see our AmnioAMP DFU case series review.

Side-by-Side Comparison Table

Feature	AmnioAMP-MP	Rampart DL Matrix
Manufacturer	NextGen Biologics	Rampart Medical
Tissue format	Dehydrated human amniotic membrane (DDHAM)	Dehydrated dual-layer human amniotic membrane
Layer count	Single layer	Dual layer
Storage	Room temperature	Room temperature
Cold chain required	No	No
Cell viability	Non-viable (matrix retained)	Non-viable (matrix retained)
Rehydration	2–3 min, sterile saline	2–3 min, sterile saline
Orientation	Side-specific (stromal side down)	Non-side specific
HCPCS code	Q4250 (per sq cm)	Q4347 (per sq cm)
CPT application codes	15271–15278	15271–15278
Published head-to-head RCTs (vs. each other)	None identified	None identified

Reimbursement and Billing (2026)

Amniotic membrane billing in 2026 operates under the CMS skin-substitute framework, where each product carries its own HCPCS Q-code billed per square centimeter. AmnioAMP-MP maps to Q4250; Rampart DL Matrix maps to Q4347. The CPT application codes 15271–15278 apply to the placement procedure regardless of which product is used.

Under the current CMS payment structure, reimbursement is product-specific rather than format-based — meaning a wound center’s margin depends on the acquisition cost of the specific product relative to its Q-code reimbursement rate. Prior authorization requirements and coverage criteria vary by payer and Medicare Administrative Contractor (MAC). Always verify the current Local Coverage Determination (LCD), product-specific coding, and payer policy before scheduling or submitting claims. Do not assume one product’s Q-code or coverage terms apply to another.

Practical Workflow and Handling

The most defensible differences between AmnioAMP and Rampart are logistical, not clinical:

• Storage and shelf life. Both products are dehydrated and room-temperature stable, eliminating the need for −20°C freezers and continuous temperature monitoring. This matters for satellite clinics, mobile wound services, and practices with limited infrastructure. Exact shelf-life claims vary by manufacturer and sterilization method — use the current product label, not a generic comparison.
• Preparation. Both require rehydration in sterile saline for 2–3 minutes before application. The rehydration is performed at the bedside and is functionally identical for both products.
• Placement. Both are applied as inlay grafts following sharp debridement and hemostasis. AmnioAMP is side-specific (stromal/basement-membrane side toward the wound bed). Rampart is non-side specific, which eliminates orientation errors and can simplify placement in anatomically challenging locations. Rampart’s dual-layer construction provides additional mechanical strength during handling for larger or geometrically complex wounds; AmnioAMP’s single-layer format conforms more readily to irregular wound surfaces.
• Reimbursement. Product-specific HCPCS Q-codes (Q4250 for AmnioAMP-MP, Q4347 for Rampart) and CPT codes 15271–15278 apply, but coverage and prior-authorization requirements vary by payer and MAC. Verify the current LCD and product-specific coding before scheduling.

For a detailed step-by-step application workflow, see our AmnioAMP application protocol guide, the Rampart clinical guide, and our neuropathic ulcer biologics protocol for loss-of-protective-sensation wounds.

Product Selection Checklist

When evaluating AmnioAMP vs Rampart for your wound care program, consider these decision factors:

• Wound geometry: For large (>4 cm²) or mechanically challenging wounds, Rampart’s dual-layer bulk offers additional handling strength. For irregular or contoured wound surfaces, AmnioAMP’s single-layer conformability may integrate more easily.
• Placement simplicity: Rampart’s non-side-specific design eliminates orientation errors. If your team places grafts in difficult anatomical locations under time pressure, this reduces a failure mode.
• Payer and coding: Confirm that the product-specific Q-code (Q4250 vs Q4347) is covered under your facility’s payer mix and MAC policy. Do not assume interchangeability.
• Regulatory status: Verify the current FDA registration status and IFU for the specific product code before use. The 2023 FDA warning letter regarding AmnioAMP-WJ underscores the importance of confirming homologous-use compliance.
• Local outcomes data: Because no head-to-head trial exists, treat your own wound-center quality data as the most relevant evidence for product selection. Track closure rates, time-to-heal, and adverse events by product in a shared registry.

FAQ

Is there a published clinical trial directly comparing AmnioAMP and Rampart?

No. Head-to-head branded product comparisons are not available in PubMed-indexed literature. Clinicians should rely on class-level evidence and manufacturer-specific instructions for use.

Does AmnioAMP-MP retain living cells?

AmnioAMP-MP is a decellularized dehydrated human amniotic membrane. The published product description emphasizes the extracellular matrix, cytokines, and growth factors — not living cells. The biologic activity is thought to derive from matrix-bound signaling molecules rather than cellular viability. The same applies to Rampart, which is also dehydrated.

Are amniotic membrane products FDA-approved drugs?

No. Amniotic membrane allografts are regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps) under section 361 of the PHS Act if they meet minimal-manipulation and homologous-use criteria, or may require FDA clearance/approval if they do not. Regulatory status varies by product and can change; verify the current classification before use.

Which product is better for diabetic foot ulcers?

The evidence base supports the amniotic membrane allograft class as an adjunct for selected DFUs after standard care has failed, but it does not rank one branded product above another. Selection should be based on wound characteristics, handling logistics, payer requirements, and the current product label. For DFU-specific treatment pathways, see our diabetic foot ulcer treatment guidelines.

Clinical Takeaway

AmnioAMP and Rampart are both dehydrated, room-temperature amniotic membrane products derived from placental tissue, but they are not interchangeable: Rampart’s dual-layer, non-side-specific format trades mechanical bulk and placement simplicity against AmnioAMP’s single-layer conformability and different HCPCS coding. The public evidence does not support specific clinical superiority claims for either product. The strongest decision factors are regulatory clarity, payer coding, handling logistics, and local quality data — not marketing comparisons.

References

1. Cooke M, et al. Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. Journal of Wound Care. 2014. PMID: 25296347.
2. Su YN, et al. Human amniotic membrane allograft, a novel treatment for chronic diabetic foot ulcers: A systematic review and meta-analysis of randomised controlled trials. International Wound Journal. 2020. PMID: 32119765.
3. Schmiedova I, et al. Clinical Evaluation of AMNIODERM+ Wound Dressing Containing Non-Viable Human Amniotic Membrane: Retrospective-Perspective Clinical Trial. BioTech (Basel). 2024. PMID: 39311338.
4. Cazzell SM, et al. Dehydrated Amnion Chorion Membrane versus standard of care for diabetic foot ulcers: a randomised controlled trial. Journal of Wound Care. 2024. PMID: 38973638.
5. Caporusso J, et al. A Multi-Centre, Randomised, Controlled Clinical Trial Assessing Cryopreserved Ultra-Thick Human Amniotic Membrane in the Treatment of Complex Diabetic Foot Ulcers. Wound Repair and Regeneration. 2025. PMID: 41346156.
6. Mohammed YA, et al. Human amniotic membrane products for patients with diabetic foot ulcers: do they help? A systematic review and meta-analysis. Journal of Foot and Ankle Research. 2022. PMID: 36104736.
7. Hu X, et al. Comparison of the efficacy of 12 interventions in the treatment of diabetic foot ulcers: a network meta-analysis. PeerJ. 2025. PMID: 40821981.